Jove
Visualize
お問い合わせ

関連する概念動画

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Landscape of copy number variants in Spanish people with dementia.

NPJ genomic medicine·2026
Same author

Quantitative sleep EEG identifies CSF core biomarker-related subgroups in Alzheimer's disease.

GeroScience·2026
Same author

[Translated article] Anticholinergic burden and its relationship with cognitive impairment in a neuropsychiatric unit.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2026
Same author

Proteomic analysis in Alzheimer's disease and other dementias: a focus on sex-specific differences.

Alzheimer's research & therapy·2026
Same author

Addressing persistent symptoms in post-COVID condition: Through a multimodal intervention delivered in two technology-based formats.

Digital health·2026
Same author

GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy.

Nature communications·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

薬物開発

María Pascual-Lucas1, Ana María Lacosta2, María Montañés2

  • 1Araclon Biotech, Zaragoza, Zaragoza, Spain.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
まとめ
この要約は機械生成です。

ABvac40ワクチンは、アルツハイマー病(AD)患者、特にアミロイドプラークを有する患者において、意味のある認知機能低下を大幅に軽減しました。ワクチンは抗体レベルが高い患者でより大きな有効性を示し、疾患修飾の可能性を示唆しています。

キーワード:
アルツハイマー病ワクチン認知機能低下アミロイドプラーク疾患修飾

さらに関連する動画

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

関連する実験動画

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学分野:

  • 神経学
  • 免疫学
  • 薬理学

背景:

  • アルツハイマー病(AD)は、血管におけるアミロイド沈着に関与するAβ40を特徴とします。
  • ABvac40は、AD治療を目的としたAβ40を標的とする開発中のワクチンです。
  • 第2相試験では、ABvac40が良好な安全性プロファイルと免疫原性を持つことが示されました。

研究 の 目的:

  • AD患者における意味のある患者内変化(MWPC)を評価することにより、ABvac40の臨床的関連性を評価すること。
  • ADの進行と認知機能低下に対するABvac40の影響を分析すること。

主な方法:

  • 軽度の認知障害またはごく軽度のAD患者を含む、無作為化二重盲検プラセボ対照第2相試験(AB1601)を実施しました。
  • 意味のある患者内変化(MWPC)は、24ヶ月にわたる2回の連続した受診でMMSEが≥3ポイント低下することと定義されました。
  • CSF抗体レベルで層別化されたMWPCのリスクを評価するために、Cox比例ハザードモデルを使用しました。

主要な成果:

  • ABvac40は、全体集団においてプラセボと比較してMWPCのリスクを53%有意に減少させました(HR=0.47; P=0.012)。
  • アミロイドPET陽性患者では、ABvac40はより顕著な効果を示し、MWPCのリスクを62%減少させました(HR=0.38; P=0.005)。
  • ワクチン接種後のCSF抗体レベルが高い患者では、MWPCのリスクが81%減少しました(HR=0.19; P=0.029)。

結論:

  • ABvac40は、特にアミロイドPET陽性者において、早期ADにおける臨床的に意味のある認知機能低下を有意に減少させます。
  • 最も強い効果は、抗体レベルが最も高い患者で観察され、用量反応関係が示唆されました。
  • 脳血管系に対するABvac40の影響と認知機能改善におけるその役割をさらに調査する必要があります。